Understanding thrombocytopenia and antigenicity with glycoprotein IIb- IIIa inhibitors

American Heart Journal

Volumn 138, Issue 4 II, 1999, Pages

  Madan, M ^a   Berkowitz, S D ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; LAMIFIBAN; TIROFIBAN;

ALGORITHM; ANTIGENICITY; CONFERENCE PAPER; DISEASE CLASSIFICATION; DISEASE SEVERITY; HUMAN; IMMUNE RESPONSE; INCIDENCE; ISCHEMIA; LIGAND BINDING; PATHOPHYSIOLOGY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA;

EID: 0032886666     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1053/hj.1999.v138.a100465     Document Type: Conference Paper

References (38)

1. Berkowitz SD, Harrington RA, Rund MM, et al. Acute profound thrombocytopenia after c7E3 Fab (abciximab) therapy. Circulation 1997;95:809-13.
2. Tcheng JE, Ellis SG, George BS, et al. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation 1994;90:1757-64.
3. Simon DI, Xu H, Ortlepp S, et al. 7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1. Arterioscler Thromb Vasc Biol 1997;17:528-35.
4. Phillips DR, Scarborough RM. Clinical pharmacology of eptifibatide. Am J Cardiol 1997;80(suppl 4A):11B-20B.
5. Deckelbaum LI, Sax FL, Grossman W. Tirofiban, a nonpeptide inhibitor of the platelet glycoprotein IIb/IIIA receptor. In: Sasahara AA, Loscalzo J, editors. New therapeutic agents in thrombosis and thrombolysis. New York, NY: Marcel Dekker; 1997. p. 355-65.
6. EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-61.
7. EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-96.
8. CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997;349: 1429-35.
9. IMPACT-II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet 1997;349:1422-8.
10. RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997;96:1445-53.
11. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998;338:1488-97.
12. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998;338:1498-505.
13. McClure MW, Berkowitz SD, Sparapani R, et al. Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome: The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Experience. Circulation 1999;99:2892-2900.
14. PARAGON Investigators. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. Circulation 1998;97:2386-95.
15. Berkowitz SD, Sane DC, Sigmon KN, et al. Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. J Am Coll Cardiol 1998;32:311-9.
16. Kereiakes DJ, Berkowitz SD, Anderson K, et al. Abciximab associated thrombocytopenia: evidence for a complex interaction with heparin [abstract]. J Am Coll Cardiol 1998;31(suppl A):55A.
17. EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998;352:87-92.
18. Kereiakes DJ, Essell JH, Abbottsmith CW, et al. Abciximab-associated profound thrombocytopenia: therapy with immunoglobulin and platelet transfusion. Am J Cardiol 1996;78:1161-3.
19. Alexander JH, Greenbaum AB, Hudson MP, et al. Session highlights from the American College of Cardiology Scientific Sessions: March 29 to April 1, 1998. Am Heart J 1998;135:1099-114.
20. Giugliano RP, Hyatt RR. Thrombocytopenia with GP IIb/IIIa inhibitors: a meta-analysis [abstract]. J Am Coll Cardiol 1998;31(suppl A):185A.
21. Simpfendorfer C, Kottke-Marchant K, Lowrie M, et al. First chronic platelet glycoprotein IIb/IIIa integrin blockade: a randomized, placebo-controlled pilot study of xemilofiban in unstable angina with percutaneous coronary interventions. Circulation 1997;96:76-81.
22. Cannon CP, McCabe CH, Borzak S, et al. Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Circulation 1998;97:340-9.
23. Madan M, Kereiakes DJ, Rund M, et al. Abciximab readministration for coronary interventions: is it safe [abstract]? Circulation 1997;96:I-162.
24. Tcheng JE, Kereiakes DJ, George BS, et al. Safety of readministration of abciximab: interim results of the ReoPro Readministration Registry (R3) [abstract]. J Am Coll Cardiol 1998;31(suppl A):55A.
25. Winkelstein A, Kiss JE. Immunohematologic disorders. JAMA 1997;278:1982-92.
26. Macchi L, Rispal P, Clofent-Sanchez G, et al. Anti-platelet antibodies in patients with systemic lupus erythematosus and the primary antiphospholipid antibody syndrome: their relationship with the observed thrombocytopenia. Br J Haematol 1997;98:336-41.
27. Bettaieb A, Oksenhendler E, Duedari N, et al. Cross-reactive antibodies between HIV-gp120 and platelet gpIIIa (CD61) in HIV-related immune thrombocytopenic purpura. Clin Exp Immunol 1996;103:19-23.
28. Dwyer JM. Manipulating the immune system with immune globulin. N Engl J Med 1992;326:107-16.
29. Warkentin T, Trimble M, Kelton J. Thrombocytopenia due to platelet destruction and hypersplenism. In: Hoffman R, Bentz EJ Jr, Shattil SJ, et al, editors. Hematology: basic principles and practice. 2nd ed. New York: Churchill Livingstone; 1995. p. 1889-909.
30. Chong BH, Xiaoping D, Berndt MC, et al. Characterization of the binding domains on platelet glycoproteins Ib-IX and IIb/IIIa complexes for the quinine/quinidine-dependent antibodies. Blood 1991;77:2190-9.
31. Curtis BR, McFarland JG, Wu GG, et al. Antibodies in sulfonamide-induced immune thrombocytopenia recognize calcium-dependent epitopes on the glycoprotein IIb/IIIa complex. Blood 1994;84:176-83.
32. Jennings LK, White MM. Expression of ligand-induced binding sites on glycoprotein IIb-IIIa complexes and the effect of various inhibitors. Am Heart J 1998;135:S179-S83.
33. Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis, frequency, avoidance and management. Drug Saf 1997;17:325-41.
34. Bednar B, Look JJ, Holahan MA, et al. Fibrinogen receptor antagonist-induced thrombocytopenia in chimpanzee and rhesus monkey associated with preexisting drug-dependent antibodies to platelet glycoprotein IIb/IIIa. Blood 1999;94:587-99.
35. Jordan RE, Wagner CL, Mascelli MA, et al. Preclinical development of c7E3 Fab; a mouse/human chimeric monoclonal antibody fragment that inhibits platelet function by blockade of GPIIb-IIIa receptors with observations on the immunogenicity of c7E3 Fab in humans. In: Horton MA, editor. Adhesion receptors as therapeutic targets. New York: CRC Press, Inc; 1996. p. 281-302.
36. Kelton JG, Sheridan D, Brain H, et al. Clinical usefulness of testing for a heparin-dependent platelet-aggregating factor in patients with suspected heparin-associated thrombocytopenia. J Lab Clin Med 1984;103:606-12.
37. Griffiths E, Dzik WH. Assays for heparin-induced thrombocytopenia. Transfus Med 1997;7:1-11.
38. Beutler E. Platelet transfusions: the 20,000/microL trigger. Blood 1993;81:1411-3.